mutations, in whom rituximab appears to possess small additional value.59 Other genomic subgroups, such as patients with BIRC3aberrations.112 Finally, the alternative BTK inhibitor acalabrutinib was a short while ago accepted through the FDA (not with the EMA nonetheless) as frontline therapy in perspective of the outcomes of the section III demo e